Video: Tasigna(R) Demonstrates Rapid Response as Initial Therapy in Life-Threatening Form of Leukemia

... may need to be increased, depending on patient tolerability. If the strong inducer is discontinued, the Tasigna dose should be reduced to the indicated dose. ... be carefully monitored, in patients receiving Gleevec with a potent CYP3A4 inducer such as rifampin or phenytoin. Examples of commonly used drugs that may ...

More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies

... be carefully monitored in patients receiving Gleevec with a potent CYP3A4 inducer such as rifampin or phenytoin. Examples of commonly used drugs that may ... may need to be increased, depending on patient tolerability. If the strong inducer is discontinued, the Tasigna dose should be reduced to the indicated dose. ...

Video: Data on More Than 15 Novartis Oncology Compounds at ASCO Highlight Progress Toward Targeted Therapies for Diverse Tumor Types

... of Gleevec should increase by at least 50%, and clinical response should be carefully monitored, in patients receiving Gleevec with a potent CYP3A4 inducer such as rifampin or phenytoin. Examples of commonly used drugs that may significantly interact with Gleevec include ketoconazole, acetaminophen, ...

ANA598 Demonstrates Potent Antiviral Activity at all Dose Levels in Completed Phase Ib Study in Hepatitis C Patients

... hepatitis C, the Company is developing two potentially complementary agents, ANA598, a non-nucleoside polymerase inhibitor and ANA773, an oral inducer of endogenous interferons that acts via the TLR7 pathway. The Company is also developing ANA773 for the treatment of cancer. Safe Harbor ...

Early Data Show Potential for Imatinib Mesylate Tablets to Treat Life-Threatening Form of Pulmonary Artery Disease

... of Gleevec should increase by at least 50%, and clinical response should be carefully monitored, in patients receiving Gleevec with a potent CYP3A4 inducer such as rifampin or phenytoin. Examples of commonly used drugs that may significantly interact with Gleevec include ketoconazole, acetaminophen, ...

Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting

... must be co-administered a strong CYP3A4 inducer, the dose of Tasigna may need to be increased, depending on patient tolerability. If the strong inducer is discontinued, the Tasigna dose should be reduced to the indicated dose. Tasigna is a competitive inhibitor of CYP3A4, CYP2C8, CYP2C9, CYP2D6, and ...

EpiCept Announces Successful Completion of Enrollment for Phase I Trial of EPC2407

... trial for EPC2407. The trial has met all of its objectives. EPC2407 is EpiCept's novel small molecule vascular disruption agent (VDA) and apoptosis inducer for the treatment of patients with advanced solid tumors and lymphomas. (Logo: http://www.newscom.com/cgi-bin/prnh/20020513/NYM112LOGO ) EpiCept ...

Ardea Biosciences, Inc. Presents Results of Phase 1 Studies of RDEA806, a Novel NNRTI for HIV, at 47th ICAAC

... RDEA806 (EC50 = 1.67 ng/ml). Evaluation of the drug-drug interaction liability, in vitro and in vivo, demonstrated that RDEA806 is unlikely to be an inducer or inhibitor of major P450 enzymes or be affected by CYP3A4 inhibitors. When given together with ritonavir, an HIV protease inhibitor and potent ...

EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound

... discovered through EpiCept's Anti-cancer Screening Apoptosis Program (ASAP). EPC2407, a novel small molecule vascular disruption agent and apoptosis inducer for the treatment of cancer patients with advanced, solid tumors and lymphomas, is currently in Phase I clinical development by EpiCept. In July ...

Myriad Genetics Presents Azixa's Mode of Action at AACR

... at the annual meeting of the American Association for Cancer Research (AACR) in Los Angeles, California. Azixa has been previously shown to be an inducer of apoptosis, and a potent inhibitor of human tumor cell growth and survival in cell culture, regardless of the multiple drug resistance ...

Mode of Action of EpiCept-Licensed Cancer Compound Profiled at AACR

... oncology programs. Notably, we are continuing with our Phase I trial of EPC2407, a novel, small molecule vascular disruption agent and apoptosis inducer for the treatment of patients with advanced solid tumors and lymphomas, which was discovered through the same Anti-cancer Screening Apoptosis Program ...

Cogane Data Presented at ‘11th International Congress of Parkinson’s Disease and Disorders’

... and a lower development cost structure. Cogane(tm) Cogane(tm) (PYM50028) is a novel non-peptide, orally bioavailable neurotrophic factor inducer that readily crosses the blood brain barrier. In pre-clinical studies, Cogane(tm) stimulates the release of neuronal growth factors, increases ...

Faust Pharmaceuticals' Phase IIa Results for Parkinson's Disease Presented at International Congress of Parkinson's Disease and Movement Disorders

... is a small molecule glutamate inhibitor in Phase II for Parkinson's disease and ALS. A second compound, FP0023, is a fetal gene activating utrophin inducer in preparation for Phase I/II for Duchenne Muscular Dystrophy. The company additionally has pre-clinical programs on targets such as mGluR ...

Late Breaking Data Released at ADA Showed that the Investigational Use of Januvia and Metformin as Initial Combination Therapy Provided Significant Glucose Lowering Efficacy over 54 Weeks in Patients with Type 2 Diabetes

... Vitro Assessment of Drug Interactions Sitagliptin is not an inhibitor of CYP isozymes CYP3A4, 2C8, 2C9, 2D6, 1A2, 2C19 or 2B6, and is not an inducer of CYP3A4. Sitagliptin is a p-glycoprotein substrate, but does not inhibit p-glycoprotein mediated transport of digoxin. Based on these results, ...

An Investigational Study Released at ADA Showed that Initial Combination Therapy with Januvia (sitagliptin) and Metformin Led to Improvement in Markers of Beta Cell Function in Patients with Type 2 Diabetes

... Vitro Assessment of Drug Interactions Sitagliptin is not an inhibitor of CYP isozymes CYP3A4, 2C8, 2C9, 2D6, 1A2, 2C19 or 2B6, and is not an inducer of CYP3A4. Sitagliptin is a p-glycoprotein substrate, but does not inhibit p-glycoprotein mediated transport of digoxin. Based on these results, ...